One in five cancer patients in Scotland is still having to wait for treatment longer than the Executive?s own two-month target. But yesterday, health minister Andy Kerr promised improvements and revealed new ways for health boards to meet targets.
?terna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers. Further data showed the compound?s good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m? which will be the recommended dose for a Phase 2 trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m? and 267 mg/m? dose levels.
On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune (nevirapine) do not prevent access to this medication in low income countries.
The HeptoVax trial is a phase II trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma (“HCC” or “liver cancer”). The trial will enrol patients from three centres in Spain, France and Germany.
Perestane?, an innovative biocidal product created and developed by Solvay, has been proven to be an effective disinfectant against Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. These so-called ?superbugs? may cause fatal diseases, and the treatment of patients with most current antibiotics is ineffective. Researchers from the University of Leeds and Leeds General Infirmary (United Kingdom) have recently demonstrated that disinfectants commonly used in hospitals fail to eradicate Clostridium difficile from the premises, and may even promote spore formation.
Researchers at Harvard Medical School’s Brigham and Women’s Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients.
Phase II clinical trial results published today in Circulation (2006;114:2374-2381) highlight the potential of a simple, once-daily dosing regimen of the novel, oral anticoagulant rivaroxaban (BAY 59-7939), a direct Factor Xa inhibitor. In this trial, rivaroxaban demonstrated that it may have similar safety and efficacy to subcutaneous enoxaparin (the current standard), for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip replacement surgery.
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
A cadre of world-renowned scientists working in the most promising areas of cancer research have come together to work as a team at one institution ? Memorial Health ? to accelerate findings for the prevention and treatment of cancer.
Implanting a small spacer between lumbar vertebrae during a procedure called interspinous process decompression may be an effective and minimally invasive way to treat spinal stenosis, according to a new report.